Neuphoria Therapeutics Stock Net Income
| NEUP Stock | 3.72 0.07 1.85% |
Neuphoria Therapeutics' fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Neuphoria Stock price.
| Last Reported | Projected for Next Year | ||
| Net Loss | -369.6 M | -351.2 M | |
| Net Loss | -13.9 M | -14.6 M | |
| Net Loss | (0.35) | (0.37) | |
| Net Income Per E B T | 0.44 | 0.76 |
Neuphoria | Net Income | Build AI portfolio with Neuphoria Stock |
Neuphoria Therapeutics Company Net Income Analysis
Neuphoria Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Neuphoria Therapeutics Net Income | (369.63 M) |
Most of Neuphoria Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neuphoria Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Neuphoria Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Neuphoria Therapeutics is extremely important. It helps to project a fair market value of Neuphoria Stock properly, considering its historical fundamentals such as Net Income. Since Neuphoria Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neuphoria Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neuphoria Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Neuphoria Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Neuphoria Therapeutics reported net income of (369.63 Million). This is 208.31% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 164.74% higher than that of the company.
Neuphoria Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neuphoria Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neuphoria Therapeutics could also be used in its relative valuation, which is a method of valuing Neuphoria Therapeutics by comparing valuation metrics of similar companies.Neuphoria Therapeutics is currently under evaluation in net income category among its peers.
Neuphoria Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Neuphoria Therapeutics from analyzing Neuphoria Therapeutics' financial statements. These drivers represent accounts that assess Neuphoria Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Neuphoria Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 15.3B | 9.5B | 4.8B | 1.2B | 11.5M | 10.9M | |
| Enterprise Value | 15.3B | 9.4B | 4.8B | 1.2B | (14.1B) | (13.4B) |
Neuphoria Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Neuphoria Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Neuphoria Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Neuphoria Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.0725 | ||||
| Profit Margin | (0.61) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 6.85 M | ||||
| Shares Outstanding | 5.38 M | ||||
| Shares Owned By Insiders | 7.74 % | ||||
| Shares Owned By Institutions | 45.87 % | ||||
| Number Of Shares Shorted | 21.72 K | ||||
| Price To Book | 1.63 X | ||||
| Price To Sales | 1.30 X | ||||
| Revenue | 23.95 M | ||||
| Gross Profit | 15.65 M | ||||
| EBITDA | (268.02 K) | ||||
| Net Income | (369.63 M) | ||||
| Total Debt | 116.31 M | ||||
| Book Value Per Share | 5.31 X | ||||
| Cash Flow From Operations | 77.23 M | ||||
| Short Ratio | 0.24 X | ||||
| Earnings Per Share | (4.02) X | ||||
| Target Price | 9.77 | ||||
| Market Capitalization | 20.38 M | ||||
| Total Asset | 28.59 B | ||||
| Retained Earnings | (178.35 B) | ||||
| Working Capital | 9.36 M | ||||
| Net Asset | 28.59 B |
About Neuphoria Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neuphoria Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuphoria Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuphoria Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Neuphoria Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neuphoria Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neuphoria Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Neuphoria Stock
Moving against Neuphoria Stock
| 0.7 | VCEL | Vericel Corp Ord | PairCorr |
| 0.64 | VCYT | Veracyte | PairCorr |
| 0.56 | VKTX | Viking Therapeutics | PairCorr |
| 0.53 | DSGN | Design Therapeutics | PairCorr |
| 0.52 | DVAX | Dynavax Technologies Trending | PairCorr |
The ability to find closely correlated positions to Neuphoria Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neuphoria Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neuphoria Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neuphoria Therapeutics to buy it.
The correlation of Neuphoria Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neuphoria Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neuphoria Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neuphoria Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Neuphoria Stock Analysis
When running Neuphoria Therapeutics' price analysis, check to measure Neuphoria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuphoria Therapeutics is operating at the current time. Most of Neuphoria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Neuphoria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuphoria Therapeutics' price. Additionally, you may evaluate how the addition of Neuphoria Therapeutics to your portfolios can decrease your overall portfolio volatility.